The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Open accessAbstract
BACKGROUND: Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited. METHODS: We performed a phase 1-2 open-label trial involving 12 participants to evaluate the safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual function over the course of 3 years. Four participants were administered a lower dose of the vector, and 8 were administered a higher dose. In a parallel study in dogs, we investigated the relationship among vector dose, visual function, and electroretinography (ERG) findings. RESULTS: Improvements in retinal sensitivity were evident, to varying extents, in six participants for up to 3 years, peaking at 6 to 12 months after treatment and then declining. No associated improvement in retinal function was detected by means of ERG. Three participants had intraocular inflammation, and two had clinically significant deterioration of visual acuity. The reduction in central retinal thickness varied among participants. In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG. CONCLUSIONS: Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit modestly and temporarily. Comparison with the results obtained in the dog model indicates that there is a species difference in the amount of RPE65 required to drive the visual cycle and that the demand for RPE65 in affected persons was not met to the extent required for a durable, robust effect. (Funded by the National Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ocular AAV therapies leading to a permanent reduction in visual acuity following intraocular inflammation (9–11)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV dose-dependent intraocular inflammation and a few instances of persistent loss of visual acuity have been independently reported in clinical trials following subretinal AAV administration despite prophylactic immunosuppression (9–11).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 1/2 dose-escalation trials for RPE65-associated LCA, choroideremia, and retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa, patients receiving higher doses of AAV have presented with various signs of retinal inflammation, including vitritis, retinitis, and choroiditis,2,6,7 implicating the presence of a cell-mediated immune response.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the perceived low immunogenicity of AAV and relative immune privilege of the intraocular environment,8 dose-dependent retinal inflammation, or gene therapy-associated uveitis (GTAU), has been observed in many retinal gene therapy trials, which limits the vector dose and therapeutic efficacy.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [45]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is clinically important as intraocular inflammation could lead to irreversible loss of retinal cells, deterioration of visual function and reduced durability of treatment effect associated with a costly one-off treatment.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, one participant developed anterior uveitis at 2 weeks, followed by CRA and reduced visual acuity by 6 months.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two participants developed optic disc swelling, retinal vascular tortuosity/sheathing and mild vitritis.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three out of eight participants who received the higher dose of vector (1 × 10 12 vg/eye) but none in the lower dose cohort (1 × 10 11 vg/eye) developed intraocular inflammation despite prophylactic peri-operative immunosuppression.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, GTAU is often diagnosed shortly after the withdrawal of systemic immunosuppression prophy laxis (Dimopoulos et al., 2018) or when the dose reaches around 15 -20 mg for slower tapers, and sometimes several weeks to months after vector administration (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredIn the citing paper
“In phase I/II clinical trials for RPE65-LCA at University College London (ClinicalTrials.gov: NCT00643747), ocular inflammation was noted following SRI of 1 × 1012 vg of AAV2-RPE65.71,99”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [99]
In the citing paper
“subfoveal viral gene therapy has been associated with various adverse effects, such as RPE alterations, retinal thinning, foveal morphological changes, vision loss, and the variable duration of clinical effects [281,294,296,297,298].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“Dose-dependent immune responses have also been observed, with high doses potentially leading to persistent inflammation and clinically significant vision loss in patients receiving high-dose AAV2 vector-based subretinal RPE65 therapy [296].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“However, some adverse events linked to the glucocorticoids themselves have already been described in retinal rAAV trials which point out the need for other alternatives to mitigate the inflammation [37].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [37]
In the citing paper
“The results showed that retinal sensitivity was improved; however, the final transgene expression in the participants from the high dose group was adversely affected by ocular inflammation or immune responses [48].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [48]
In the citing paper
“Nonetheless, inflammatory reactions to gene therapy in the eye have led to permanent vision loss for some patients7–9.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Self-citationStatistics Notes: Measurement error
Bland, J. M., & Altman, D. G. (1996) · BMJ · doi:10.1136/bmj.313.7059.744 · Cited by 1,084
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Leber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811
Cideciyan, A. V., Alemán, T. S., Boye, S. L., Schwartz, S., Kaushal, S., Román, A. J., Pang, J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 674
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Research works printed but not linked: 3
- Poehner WJ, 2000, Mol Vis, 6, 192
- Geller SF, 2001, Invest Ophthalmol Vis Sci, 42, 1363
- 10.1056/NEJMoa1412965 · DOI
Cited by
Sorted by citations
Items 601–700 of 743
Gene Transfer Strategies and Applications in Genetic Diseases
Brunetti‐Pierri, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_1 · Cited by 2
RPE65 Mutation-associated Inherited Retinal Disease and Gene Therapies
Camp, D. A., Falabella, P., & Ciulla, T. A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000381 · Cited by 2
Leber Congenital Amaurosis/Early-Onset Severe Retinal Dystrophy
Georgiou, M., & Michaelides, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-7337-5_6 · Cited by 2
Self-citationStem Cell and Gene Therapy for Inherited Retinal Diseases
DeSouza, P. J., Park, U. C., & Park, S. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-7337-5_3 · Cited by 2
The Role of Ceramide in Inherited Retinal Disease Pathology
Qian, X., Srinivasan, T., He, J., & Chen, R. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-27681-1_44 · Cited by 2
Genetics of the Retinal Dystrophies
Merepa, S. S., Broadgate, S., Sekaran, S., & Halford, S. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0028116 · Cited by 2
Reichel, F. F., Király, P., Seitz, I. P., & Fischer, M. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073705 · Cited by 1
Immunology of cell and gene therapy approaches for neurologic diseases
Widner, H. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00018-6 · Cited by 1
Ocular toxicity, distribution, and shedding of intravitreal AAV-eqIL-10 in horses
Young, K., Hasegawa, T., Vridhachalam, N., Henderson, N., Salmon, J. H., McCall, T. F., Hirsch, M. L., & Gilger, B. C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101360 · Cited by 1
Li, B., Zhao, C., Guo, S., Li, X., Zhang, H., Duan, Y., Zhang, M., Tao, Q., Zhou, P., Li, X., et al. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110273 · Cited by 2
Female Simplex Carriers of X-Linked Retinal Dystrophies: A Case Series
Delaney, A., Branham, K. E. H., Jayasundera, T., Khan, N., & Fahim, A. T. (2025) · Case Reports in Ophthalmology · doi:10.1159/000546129 · Cited by 1
Biotechnology in Medicine: Fundamentals
Nigam, M., Singh, N., Dimri, D. B., & Mishra, A. P. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-96-4959-4_1 · Cited by 1
Upadhyay, A. K., Drag, S., Singh, P., Rajanala, K., & Arumugham, R. G. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1679619 · Cited by 1
Ren, D., Chauveau, G. A., Cabon, E., Vendomèle, J., Vignal‐Clermont, C., Saliba, H., Ail, D., Dalkara, D., & Fisson, S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101443 · Cited by 1
Langer, P. M., Clare, A. J., Peng, X., Costello, K. L., Cendanawati, S., Wilson, L. L., Ward, A., Bell, O. H., Chu, C. J., Chan, Y., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.018 · Cited by 1
Choi, S. Y., Cho, C. S., Kim, S., Kim, J. Y., Kim, H. K., Kim, K. H., Jo, D. H., & Lee, H. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124226 · Cited by 1
Modalities of vision restoration in optic neuropathies and retinal disease
Rubin, B. R., Lavinsky, F., Cain, R., Kuriyan, A. E., Wollstein, G., Zambrano, R., & Schuman, J. S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101474 · Cited by 1
Insights into retinal remodeling in retinal degenerative disease
Jones, B. W. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00015-x · Cited by 2
Inherited retinal degenerations: clinical phenotypes and emerging therapies
Uyhazi, K. E., O'Neil, E. C., Alemán, T. S., & Cideciyan, A. V. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00766-x · Cited by 1
Quantification of Ocular Gene Therapy–Related Inflammation Using the VRMACS Grading System
Elsayed, M. E. A. A., & MacLaren, R. E. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101316 · Cited by 1
Leber's hereditary optic neuropathy: Report of a simple case associated with a rare variant mutation
Malhotra, R. M., Mejally, M. A. A., Abualela, H., & Eltemamy, M. (2016) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.194314 · Cited by 1
Retinitis Pigmentosa in Japanese Population
Hosono, K., Minoshima, S., & Hotta, Y. (2017) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-4-431-56511-6_11 · Cited by 1
Vasconcelos, F., & Daniel, L. (2017) · Cited by 1
Uncovering the role of microRNA-206 in Duchenne muscular dystrophy
Bulaklak, K. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/t7cv-fc67 · Cited by 1
Gentherapie in der Pädiatrie – bereits Realität oder noch immer Fiktion?
Bartholdi, D. (2019) · Pädiatrie up2date · doi:10.1055/s-0043-115206
Stem Cell Based Exosomes: Are They Effective in Disease or Health?
Kucukguven, M. B., & Çelebi‐Saltik, B. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_630 · Cited by 1
Gene Therapy, Diet and Drug Approaches to Treating Inherited Retinal Disease
Simunovic, M. P., Mack, H. G., Ayton, L. N., & Hassall, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00154-7 · Cited by 1
Gacar, G., Ünal, E. D., & Yusufoğlu, S. (2021) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.818 · Cited by 1
Tuszynski, M. H. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_1 · Cited by 1
Visual Impairment in Infants and Young Children
Fulton, A. B., & Yang, P. G. (2020) · Springer eBooks · doi:10.1007/978-3-319-90495-5_279-1 · Cited by 1
Ocular Gene Therapy: Literature Review
Naser, M., Nasr, M., & Shehata, L. H. (2023) · International Journal of Progressive Sciences and Technologies · doi:10.52155/ijpsat.v40.2.5623 · Cited by 1
Şahin, İ., Erdem, H. B., Bahsi, T., & Saat, H. (2024) · Cureus · doi:10.7759/cureus.53742 · Cited by 1
Neitz, M., & Neitz, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-815234-8.00012-4 · Cited by 1
Diminution of Early Gene Therapy Success for Childhood Blindness
(2015) · AAP Grand Rounds · doi:10.1542/gr.34-2-22 · Cited by 1
Amaurosis congénita de Leber RPE-65, seguimiento a 7 años
Sánchez-Ramos, J. A., Hernández-Vázquez, Á. Y., & Ramírez-Estudillo, J. A. (2017) · Gaceta Médica de México · doi:10.24875/gmm.17002945 · Cited by 1
Stieger, K., & Lorenz, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-28384-1_15 · Cited by 2
Innovative Strategies for Treating Retinal Diseases
Straňák, Z., Kousal, B., Ardan, T., & Veith, M. (2019) · Czech and Slovak Ophthalmology · doi:10.31348/2019/6/1 · Cited by 1
Hassall, M., & Simunovic, M. P. (2020) · Springer eBooks · doi:10.1007/978-981-15-7644-7_35 · Cited by 1
Takahashi, K., Igarashi, T., Miyake, K., Kobayashi, M., Katakai, Y., Hayashita‐Kinoh, H., Fujimoto, C., Kameya, S., Takahashi, H., & Okada, T. (2021) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2021_88-203 · Cited by 1
Nanoparticles as Cell Tracking Agents in Human Ocular Cell Transplantation Therapy
Mundy, D. C., & Goldberg, J. L. (2021) · Current Ophthalmology Reports · doi:10.1007/s40135-021-00275-z · Cited by 1
Jo, D. H., Kim, J. H., & Kim, J. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817876-8.00001-2 · Cited by 1
Opportunities and challenges of gene therapy for retinitis pigmentosa
Luo, X., Liu, Y., FengHua, W. A. N. G., & Sun, X. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0012 · Cited by 1
AAV-mediated CRISPR/Cas gene editing of retinal cells in vivoPreprint
Hung, S. S., Chrysostomou, V., Li, F., Lim, J. K., Wang, J.-H., Powell, J. E., Tu, L., Daniszewski, M., Lo, C., Wong, R. C., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/039156 · Cited by 1
Forging the Fate of Cellular Therapies for Cardiovascular Disease
Simari, R. D. (2017) · Circulation Research · doi:10.1161/circresaha.117.310970 · Cited by 1
Management and treatment of inherited retinal dystrophies
Levi, S. R., Jenny, L. A., & Tsang, S. H. (2021) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_32_21 · Cited by 1
Immunogenicity of AAV Gene Therapy Products
Jawa, V., & Wu, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch5 · Cited by 1
Ren, D., Chauveau, G. A., Vendomèle, J., Cabon, E., Pineiro, A., Vignal‐Clermont, C., Saliba, H., Ronzitti, G., Galy, A. H. M., Dalkara, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.02.656863 · Cited by 1
Bunel, M. (2017) · theses.fr (ABES) · doi:10.70675/2c39f34dz974dz470bzb45azca176b38a75e · Cited by 1
Should the next step in glaucoma treatment be alternative drug therapies rather than gene therapy?
Kaufman, P. L. (2016) · Expert Review of Ophthalmology · doi:10.1080/17469899.2017.1269603
Leber Congenital Amaurosis/Early-Onset Retinal Dystrophy in Japanese Population
Kuniyoshi, K., & Shimomura, Y. (2017) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-4-431-56511-6_13
Strategies for Restoring Vision by Transducing a Channelrhodopsin Gene into Retinal Ganglion Cells
Tomita, H., & Sugano, E. (2017) · Cambridge University Press eBooks · doi:10.1017/9781107281875.028
The Next Generation Sequencing Based Molecular Diagnosis of Visual Diseases
Wang, X., & Lewis, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56418-0_4
Designer Effectors for Editing and Regulating Complex Genomes
Müller, M., Mlambo, T., & Mussolino, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_7
Gentherapie zur Behandlung von Netzhauterkrankungen
Ochakovski, G. A., Bartz‐Schmidt, K. U., & Fischer, M. D. (2017) · Medizinische Genetik · doi:10.1007/s11825-017-0133-7
Sobre la terapia génica para enfermedades de la retina
Fischer, M. D. (2017) · Ophthalmologica · doi:10.1159/000477516
Postępowanie w zwyrodnieniu barwnikowym siatkówki – przegląd piśmiennictwa
Krasodomska, K., & Lubiński, W. (2017) · Pomeranian Journal of Life Sciences · doi:10.21164/pomjlifesci.279
Graca, A. B. (2017) · UCL Discovery (University College London)
Challenges to Clinical Trial Design for Emerging Regenerative Technologies
Tuzon, C. T., & RICHMOND, F. J. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65584-8
Development of gene therapy using genome editing technology
Onodera, M. (2018) · Journal of Hematopoietic Cell Transplantation · doi:10.7889/hct-17-014
The Implications of CRISPR-Cas9 Genome Editing for IR
Perkons, N. R., Sheth, R. A., Ackerman, D., Chen, J. X., Saleh, K. S., Hunt, S. J., Nadolski, G., Shi, J., & Gade, T. P. F. (2018) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.02.027
Leber congenital amaurosis RPE65: 7 years follow up
Sánchez-Ramos, J. A., Hernández-Vázquez, Á. Y., & Ramírez-Estudillo, J. A. (2018) · Gaceta Médica de México · doi:10.24875/gmm.m18000099
Diagnostic and therapeutic challenges in inflammatory eye diseases
Wieringa, W. G. (2019) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Shu, Y., Yao, J., Qu, Y., Zheng, J., Ding, J., Zhang, L., Wang, Y., Zhao, L., Zhang, J., & Tang, S. (2019) · Oncology and Translational Medicine · doi:10.1007/s10330-018-0313-3 · Cited by 1
Rosolen, S. G. (2016) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30568-0
Newer Technologies in Vitreoretinal Disorders
Ayachit, A., & Chhablani, J. K. (2019) · Current practices in ophthalmology · doi:10.1007/978-981-13-9795-0_5
An Update on Ocular Gene Therapy for Monogenic and Multifactorial Retinal Diseases
Hou, A. Y., & Kiss, S. (2019) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126419876750
Leber congenital amaurosis in a young female
Connelly, A. M., & Grosel, J. M. (2019) · JAAPA · doi:10.1097/01.jaa.0000580540.26228.6b
Combining tissue engineering and gene delivery to enhance peripheral nerve regeneration
Busuttil, F. (2019) · UCL Discovery (University College London)
Gene therapy for childhood neuromuscular and neurodegenerative disorders: An update
Panda, P. (2019) · Indian Journal of Health Sciences and Biomedical Research (KLEU) · doi:10.4103/kleuhsj.kleuhsj_81_19
Gene formulations, gene prescriptions
Bieńkowska, A., Słyk, Ż., Banaczkowska-Duda, E., & Małecki, M. (2018) · Farmacja Polska · doi:10.32383/farmpol/118670
Development of CRISPR/Cas-mediated gene editing in the retina
Li, F. (2020) · UTAS Research Repository · doi:10.25959/23249972
Wei, Z., Liu, X., Li, T., Li, X., Zhou, Q., Wu, J., & Zhang, C. (2021) · Future Virology · doi:10.2217/fvl-2020-0096
Retinal Surgical Techniques for Gene Therapy
Muthiah, M. N., Wong, S. C., Michaelides, M., & Bainbridge, J. W. (2021) · Springer eBooks · doi:10.1007/978-981-33-4168-5_35
Self-citationMultiplex viral tropism assay in complex cell populations with single-cell resolutionPreprint
Keng, C. T., Guo, K., Lim, D. S., & Chew, W. L. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.12.451549
Innate Immunity and the Retinal Pigment Epithelium in Gene Therapy for Inherited Retinal Disorders
Casey, G. A. (2021) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-px5t-6n74
Moodle:データベース構築の実際(2)「小テスト」と「オンラインテキスト」について
表, 正. (2010)
Kick, G. R. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/88127
Linsenmeier, R. A., & Troy, J. B. (2020) · Springer eBooks · doi:10.1007/978-3-030-43395-6_21
Chou, H., Wu, A., Cheng, Y.-C., & Wang, N. (2020) · Retina atlas · doi:10.1007/978-981-15-0414-3_1
Diagnosis and Complementary Examinations
Lew, Y. J., & Duncan, J. L. (2019) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-030-05222-5_11
RNA Base Editing Technologies for Gene Therapy
Deswal, S. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch15
From Bench to Bedside: Herausforderungen in der Entwicklung von gentherapeutischen Ansätzen
Priglinger, C., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1739-3825
Grigorenko, E. L. (2022) · Springer eBooks · doi:10.1007/978-3-319-98390-5_62-1
The Effect of Age on Gene Therapy Efficacy for RPE65 Leber’s Congenital Amaurosis: A Pooled Analysis
Tian, M., & Bhatia, S. K. (2022) · Proceedings of the World Congress on New Technologies · doi:10.11159/icbb22.009
Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia
Кадышев, В. В., Zolnikova, I. V., Khalanskaya, O. V., Stepanova, A. A., & Kutsev, S. I. (2022) · Russian Annals of Ophthalmology · doi:10.17116/oftalma202213804149
Publication Trends of Leber Congenital Amaurosis Researches: A Bibliometric Study during 2002-2021Preprint
Huang, X., Wang, Y., Xie, M., Zhao, X., Chen, Y., Chen, J., Han, S., Zhou, M., & Sun, X. (2022) · Research Square · doi:10.21203/rs.3.rs-2108855/v1
Vendomèle, J., Chauveau, G. A., Dalkara, D., Galy, A. H. M., & Fisson, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.30.522324
Grigorenko, E. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-90913-0_62
Silva, V. D. O. E., Mendes, J. K. D. S., de Barros, V. A., Maximino, M. D. S., Medeiros, L., & da Silva, A. H. P. (2023) · Revista Brasileira de Oftalmologia · doi:10.37039/1982.8551.20230041
Gene Therapy for Ophthalmic Diseases
Igarashi, T. (2023) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.19.242
Stieger, K., & Lorenz, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-35055-9_15
Amaurose congênita de Leber: relato de caso e revisão da literatura
de Araujo, S. A. V., Neumann, R. Z., Monticuco, V. G. E., Almeida, B. R., & Cyrino, F. V. R. (2021) · eOftalmo · doi:10.17545/eoftalmo/2021.0026
de Guimarães, T. A. C., & Michaelides, M. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_16
Self-citationPublication trends of Leber congenital amaurosis researches: a bibliometric study during 2002-2022
Huang, X.-X., Xie, M., Sun, Y.-Q., Zhao, X., Chen, Y., Chen, J., Han, S.-Y., Zhou, M., & Sun, X. (2024) · International Journal of Ophthalmology · doi:10.18240/ijo.2024.08.17
Future Strategies for Optic Nerve Protection and Repair
Cankurtaran, M. (2024) · Güncel Retina Dergisi (Current Retina Journal) · doi:10.37783/crj-0457
Varela, M. D., Hashem, S. A., Sumodhee, D., & Michaelides, M. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.12.9
Self-citationKim, S. R., Kim, J. H., Yoon, W. T., & Lew, Y. J. (2025) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2025.66.1.36
A New Step Forward in Gene Therapy Research for Kidney Diseases
Atta, M. G. (2025) · Kidney News · doi:10.62716/kn.000162024
Metadata
- Authors
- Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., Feathers, K. L., Luong, V. A., Yzer, S., Balaggan, K., Viswanathan, A., de Ravel, T. J. L., Casteels, I., Holder, G. E., Tyler, N., Fitzke, F. W., Weleber, R. G., Nardini, M., Moore, A. T., Thompson, D. A., Petersen-Jones, S. M., Michaelides, M., van den Born, L. I., Stockman, A., Smith, A. J., Rubin, G., & Ali, R. R.
- Affiliations
- Moorfields Eye Hospital (GB)
- Michigan State University (US)
- University of Michigan (US)
- Rotterdam Eye Hospital (NL)
- Universitair Ziekenhuis Leuven (BE)
- Oregon Health & Science University (US)
- ORCID
- Bainbridge, James W.B.
- Sundaram, Venki
- Robbie, Scott J.
- Georgiadis, Anastasios
- Mowat, Freya M.
- Beattie, Stuart G.
- Yzer, Suzanne
- Balaggan, Kamaljit
- Viswanathan, Ananth
- Casteels, Ingele
- Holder, Graham E.
- Tyler, Nick
- Weleber, Richard G.
- Moore, Anthony T.
- Thompson, Debra A.
- Michaelides, Michel
- Smith, Alexander J.
- Rubin, Gary
- Ali, Robin R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1887-1897
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4497809
- OpenAlex
- W265142245
- Semantic Scholar
- 31832b3aa3500171fc5f2a951f0a4124bd40068d
- Cited by
- 743
- References
- 29
- Citations by year
- 2026: 36 · 2025: 36 · 2024: 46 · 2023: 44 · 2022: 63 · 2021: 92 · 2020: 81 · 2019: 68 · 2018: 79 · 2017: 97 · 2016: 72 · 2015: 27
- FWCI
- 39.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Durham Research Online (Durham University) (acceptedVersion)
- Durham Research Online (Durham University) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Wellcome Trust
- Massachusetts Medical Society
- National Institute for Health and Care Research (NF-SI-0507-10204, NF-SI-0513-10074, NIHR-RP-011-003)
- Sir Jules Thorn Charitable Trust
- University College London
- European Commission
- Ulverscroft Foundation
- Durham University
- KU Leuven
- Moorfields Eye Hospital NHS Foundation Trust
- Directorate for Biological Sciences
- Medical Research Council (MR/K024000/1, MR/M015815/1, MR/J005215/1)
- Engineering and Physical Sciences Research Council (EP/J017698/1, EP/J005193/1)
- Biotechnology and Biological Sciences Research Council (BB/M00211X/1)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, retinal degeneration, visual function, retinal sensitivity, electroretinogram, vector dose, intraocular inflammation, visual acuity, canine model, species differences, long-term efficacy and safety
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Animals, Child, Disease Models, Animal, Dogs, Genetic Vectors, Humans, Mutation, Retina, Vision, Ocular, Genetic Therapy, DNA, Complementary, Disease Progression, cis-trans-Isomerases, Photoreceptor Cells, Vertebrate, Young Adult, Leber Congenital Amaurosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
